Safety and efficacy of montelukast as adjunctive therapy for treatment of asthma in elderly patients

Clinical Interventions in Aging

Volumn 8, Issue , 2013, Pages 1329-1337

  Scichilone, Nicola ^a   Battaglia, Salvatore ^a   Benfante, Alida ^a   Bellia, Vincenzo ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Aging; Airway inflammation; Asthma; Leukotriene antagonists; Treatment

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUTICASONE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LEUKOTRIENE; LEUKOTRIENE D4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; MONTELUKAST; PEPTIDOLEUKOTRIENE; PLACEBO; PRANLUKAST; ZAFIRLUKAST; ZILEUTON;

ABDOMINAL PAIN; ACUTE HEPATITIS; ADD ON THERAPY; ADJUVANT THERAPY; AGED; ALLERGIC ASTHMA; ALLERGY; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHOSPASM; CARDIOVASCULAR DISEASE; CHURG STRAUSS SYNDROME; COMBINATION CHEMOTHERAPY; DETERIORATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EOSINOPHIL COUNT; EOSINOPHILIA; FORCED EXPIRATORY VOLUME; GERIATRIC PATIENT; HEADACHE; HEARTBURN; HUMAN; INFECTION; MAINTENANCE THERAPY; MONOTHERAPY; NAUSEA; PATIENT COMPLIANCE; RESPIRATORY TRACT ALLERGY; RESPIRATORY TRACT INFLAMMATION; REVIEW; SECONDARY PREVENTION; SINUSITIS; UNSPECIFIED SIDE EFFECT;

AGING; AIRWAY INFLAMMATION; ASTHMA; LEUKOTRIENE ANTAGONISTS; TREATMENT;

ACETATES; AGED; AGED, 80 AND OVER; ANTI-ASTHMATIC AGENTS; ASTHMA; FEMALE; HUMANS; MALE; MIDDLE AGED; QUINOLINES;

EID: 84885052473     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/CIA.S35977     Document Type: Review

References (51)

1. Zureik M, Orehek J. Diagnosis and severity of asthma in the elderly: results of a large survey in 1,485 asthmatics recruited by lung specialists. Respiration. 2002;69(3):223-228.
2. World Health Organization. Ageing and life course. 2013. Available from: http://www.who.int/ageing/en/. Accessed July 25, 2013.
3. Bellia V, Pedone C, Catalano F, et al. Asthma in the elderly: mortality rate and associated risk factors for mortality. Chest. 2007;132(4): 1175-1182.
4. Braman SS, Kaemmerlen JT, Davis SM. Asthma in the elderly. A comparison between patients with recently acquired and long-standing disease. Am Rev Respir Dis. 1991;143(2):336-340.
5. Connolly MJ, Crowley JJ, Charan NB, Nielson CP, Vestal RE. Reduced subjective awareness of bronchoconstriction provoked by methacholine in elderly asthmatic and normal subjects as measured on a simple awareness scale. Thorax. 1992;47(6):410-413.
6. Cuttitta G, Cibella F, Bellia V, et al. Changes in FVC during methacholine-induced bronchoconstriction in elderly patients with asthma: bronchial hyperresponsiveness and aging. Chest. 2001;119(6):1685-1690.
7. Ekici M, Apan A, Ekici A, Erdemoglu AK. Perception of bronchoconstriction in elderly asthmatics. J Asthma. 2001;38(8):691-696.
8. Law M, Morris JK, Wald N, Luczynska C, Burney P. Changes in atopy over a quarter of a century, based on cross sectional data at three time periods. BMJ. 2005;330(7501):1187-1188.
9. Linneberg A, Gislum M, Johansen N, Husemoen LL, Jorgensen T. Temporal trends of aeroallergen sensitization over twenty-five years. Clin Exp Allergy. 2007;37(8):1137-1142.
10. Scichilone N, Augugliaro G, Togias A, Bellia V. Should atopy be assessed in elderly patients with respiratory symptoms suggestive of asthma? Expert Rev Respir Med. 2010;4(5):585-591.
11. Mathur SK, Schwantes EA, Jarjour NN, Busse WW. Age-related changes in eosinophil function in human subjects. Chest. 2008;133(2): 412-419.
12. Fabbri LM, Romagnoli M, Corbetta L, et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;167(3):418-424.
13. ten Brinke A, Zwinderman AH, Sterk PJ, Rabe KF, Bel EH. Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med. 2001;164(5):744-748.
14. Di Lorenzo G, Mansueto P, Ditta V, et al. Similarity and differences in elderly patients with fixed airflow obstruction by asthma and by chronic obstructive pulmonary disease. Respir Med. 2008;102(2):232-238.
15. Grayson MH, Korenblat PE. Treating asthma in the older patient: is there a place for leukotriene modifiers? Drugs Aging. 2006;23(6):451-459.
16. Back M, Kumlin M, Cotgreave IA, Dahlen SE. An alternative pathway for metabolism of leukotriene D(4): effects on contractions to cysteinyl-leukotrienes in the guinea-pig trachea. Br J Pharmacol. 2001;133(7): 1134-1144.
17. Mechiche H, Naline E, Candenas L, et al. Effects of cysteinyl leukotrienes in small human bronchus and antagonist activity of montelukast and its metabolites. Clin Exp Allergy. 2003;33(7):887-894.
18. Barnes NC, Pujet JC. Pranlukast, a novel leukotriene receptor antagonist: results of the first European, placebo controlled, multicentre clinical study in asthma. Thorax. 1997;52(6):523-527.
19. Barnes NC, Miller CJ. Effect of leukotriene receptor antagonist therapy on the risk of asthma exacerbations in patients with mild to moderate asthma: an integrated analysis of zafirlukast trials. Thorax. 2000;55(6):478-483.
20. Horiguchi T, Tachikawa S, Kondo R, Shiga M, Hirose M, Ito T. Clinical effects of long-term administration of pranlukast, a leukotriene receptor antagonist, on adult patients with bronchial asthma. Arzneimittelforschung. 2003;53(10):714-721.
21. Vaquerizo MJ, Casan P, Castillo J, et al. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax. 2003;58(3):204-210.
22. Bozek A, Warkocka-Szoltysek B, Filipowska-Gronska A, Jarzab J. Montelukast as an add-on therapy to inhaled corticosteroids in the treatment of severe asthma in elderly patients. J Asthma. 2012;49(5):530-534.
23. Barnes N, Thomas M, Price D, Tate H. The national montelukast survey. J Allergy Clin Immunol. 2005;115(1):47-54.
24. Ohshima N, Matsui H, Matsui Y, et al. Addition of leukotriene receptor antagonists to inhaled corticosteroids improved QOL of patients with bronchial asthma surveyed in suburban Tokyo, Japan. Allergol Int. 2011;60(4):473-481.
25. Yasui H, Fujisawa T, Inui N, et al. Impact of add-on pranlukast in stable asthma; the additive effect on peripheral airway inflammation. Respir Med. 2012;106(4):508-514.
26. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2012. Available from: http://www.ginasthma.org/. Accessed August 27, 2013.
27. Dahlen SE, Malmstrom K, Nizankowska E, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165(1):9-14.
28. Camargo CA Jr, Smithline HA, Malice MP, Green SA, Reiss TF. A randomized controlled trial of intravenous montelukast in acute asthma. Am J Respir Crit Care Med. 2003;167(4):528-533.
29. Camargo CA Jr, Gurner DM, Smithline HA, et al. A randomized placebo-controlled study of intravenous montelukast for the treatment of acute asthma. J Allergy Clin Immunol. 2010;125(2):374-380.
30. National Asthma Education and Prevention Program. Considerations for diagnosing and managing asthma in the elderly. NIH publication 1996; No 96-3662. Available from: http://msdh.ms.gov/msdhsite/_static/resources/2107/pdf. Accessed July 26, 2013.
31. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005;127(1):335-371.
32. Laforest L, Denis F, Van Ganse E, et al. Correlates of adherence to respiratory drugs in COPD patients. Prim Care Respir J. 2010;19(2): 148-154.
33. Scichilone N, Spatafora M, Battaglia S, Arrigo R, Benfante A, Bellia V. Lung penetration and patient adherence considerations in the management of asthma: role of extra-fine formulations. J Asthma Allergy. 2013;6:11-21.
34. Gangemi S, Pescara L, D'Urbano E, et al. Aging is characterized by a profound reduction in anti-inflammatory lipoxin A4 levels. Exp Gerontol. 2005;40(7):612-614.
35. Vachier I, Bonnans C, Chavis C, et al. Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound. J Allergy Clin Immunol. 2005;115(1):55-60.
36. Korenblat PE, Kemp JP, Scherger JE, Minkwitz MC, Mezzanotte W. Effect of age on response to zafirlukast in patients with asthma in the Accolate Clinical Experience and Pharmacoepidemiology Trial (ACCEPT). Ann Allergy Asthma Immunol. 2000;84(2):217-225.
37. Creticos P, Knobil K, Edwards LD, Rickard KA, Dorinsky P. Loss of response to treatment with leukotriene receptor antagonists but not inhaled corticosteroids in patients over 50 years of age. Ann Allergy Asthma Immunol. 2002;88(4):401-409.
38. Nyenhuis SM, Schwantes EA, Mathur SK. Characterization of leukotrienes in a pilot study of older asthma subjects. Immun Ageing. 2010;7:8.
39. Horiguchi T, Tachikawa S, Kondo R, et al. Comparative evaluation of the leukotriene receptor antagonist pranlukast versus the steroid inhalant fluticasone in the therapy of aged patients with mild bronchial asthma. Arzneimittelforschung. 2007;57(2):87-91.
40. Williams B, Noonan G, Reiss TF, et al. Long-term asthma control with oral montelukast and inhaled beclomethasone for adults and children 6 years and older. Clin Exp Allergy. 2001;31(6):845-854.
41. Rand C, Bilderback A, Schiller K, Edelman JM, Hustad CM, Zeiger RS. Adherence with montelukast or fluticasone in a long-term clinical trial: results from the mild asthma montelukast versus inhaled corticosteroid trial. J Allergy Clin Immunol. 2007;119(4):916-923.
42. Storms W, Michele TM, Knorr B, et al. Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged 6 years. Clin Exp Allergy. 2001;31(1):77-87.
43. Pearlman DS, White MV, Lieberman AK, et al. Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma. Ann Allergy Asthma Immunol. 2002;88(2): 227-235.
44. Robinson DS, Campbell D, Barnes PJ. Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial. Lancet. 2001;357(9273):2007-2011.
45. Virchow JC, Bachert C. Efficacy and safety of montelukast in adults with asthma and allergic rhinitis. Respir Med. 2006;100(11):1952-1959.
46. Russmann S, Iselin HU, Meier D, et al. Acute hepatitis associated with montelukast. J Hepatol. 2003;38(5):694-695.
47. Tuggey JM, Hosker HS. Churg-Strauss syndrome associated with montelukast therapy. Thorax. 2000;55(9):805-806.
48. Back M. Leukotriene signaling in atherosclerosis and ischemia. Cardiovasc Drugs Ther. 2009;23(1):41-48.
49. Ingelsson E, Yin L, Back M. Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease. J Allergy Clin Immunol. 2012;129(3):702-707. e702.
50. Hanania NA, King MJ, Braman SS, et al. Asthma in the elderly: Current understanding and future research needs-a report of a National Institute on Aging (NIA) workshop. J Allergy Clin Immunol. 2011; 128(Suppl 3):S4-S24.
51. Jayaram L, Duong M, Pizzichini MM, et al. Failure of montelukast to reduce sputum eosinophilia in high-dose corticosteroid-dependent asthma. Eur Respir J. 2005;25(1):41-46.